BrainStorm Cell Therapeutics Inc.
335 articles with BrainStorm Cell Therapeutics Inc.
Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer's Disease program on July 8, 2020 at 8:15 AM ET
BrainStorm Cell Therapeutics Inc. announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that it has been granted Small and Medium-Sized Enterprise status by the European Medicines Agency’s Micro, Small and Medium-Sized Enterprise office.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST,
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced Dr. Ralph Kern, M.D, President and Chief Medical Officer will present a corporate overview during the BIO International Convention, which has transitioned to a new and virtual event and has been renamed BIO Digital.
The fully enrolled placebo-controlled Phase 3 trial is evaluating NurOwn® investigational treatment in ALS patients
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced a lease agreement with the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel, to produce NurOwn® in three state-of-the-art cleanrooms.
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the first quarter ended March 31, 2020 and recent corporate updates.
BrainStorm Cell Therapeutics Inc. announced that new data highlighting the immunomodulatory effects of NurOwn® on B and T regulatory function appeared in an online supplement to Neurology.
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 a.m. EDT
BrainStorm-Cell Therapeutics Inc., a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020.
BrainStorm Cell Therapeutics Inc. announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority.
4/3/2020Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.
International Pharmaceutical Veteran to Lead Global Business and Commercial Development
BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors
Prof. Frenkel, Chairman of the Group of Thirty (G-30) Board of Trustees, Former Chairman of JPMorgan Chase International and Former Governor of the Bank of Israel Joins the Board to Support the Company’s Global Expansion
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones
BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office based in Miami, Florida, in connection with a privately negotiated sale of common stock and a warrant to purchase common stock (collectively, the “securities”).
3/2/2020The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial
BrainStorm Cell Therapeutics Inc. announced that Partners MS Center at Brigham and Women’s Hospital, a leading research and clinical care center, has contracted with BrainStorm as a clinical study site for the Company’s Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn® in participants with progressive Multiple Sclerosis.
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 Conference Call and Webcast @ 8:00 a.m. Eastern Time Today
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.